Cargando…

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients

BACKGROUND: Insufficient and contradictory data are available about the relation between direct-acting antivirals (DAAs) and hepatocellular carcinoma (HCC) development in patients with hepatitis C virus (HCV). AIM: To analyze differences in basic clinical, radiological, and laboratory characteristic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fouad, Magdy, El Kassas, Mohamed, Ahmed, Elham, El Sheemy, Reem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Control Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637672/ https://www.ncbi.nlm.nih.gov/pubmed/34904042 http://dx.doi.org/10.4254/wjh.v13.i11.1743

Ejemplares similares

Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations
por: El Kassas, Mohamed, et al.
Publicado: (2020)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review
por: El Kassas, Mohamed, et al.
Publicado: (2019)

Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure
por: Mohamed, Hala, et al.
Publicado: (2022)

Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2020)

Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves
por: El Kassas, Mohamed, et al.
Publicado: (2019)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma
por: Wahb, Amany Mohamed Salah Eldin, et al.
Publicado: (2021)

Prospective Comparison of Hepatocellular Carcinoma Behavior and Survival of Patients who Did or Did not Receive HCV Direct-Acting Antivirals
por: El-Kassas, Mohamed, et al.
Publicado: (2023)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

New era for management of chronic hepatitis C virus using direct antiviral agents: A review
por: Elbaz, Tamer, et al.
Publicado: (2015)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

The effect of different direct antivirals on hepatic steatosis in nondiabetic and naïve hepatitis C-infected Egyptian patients
por: El-Ghandour, Ahmed, et al.
Publicado: (2023)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus
por: Ghanem, Samar Ebrahim, et al.
Publicado: (2021)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals
por: Noureddin, Mazen, et al.
Publicado: (2018)

Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience
por: Kaneko, Rena, et al.
Publicado: (2018)

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
por: Gountas, Ilias, et al.
Publicado: (2019)

Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment
por: Tan, Ning, et al.
Publicado: (2021)

The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022)

Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C–Related Advanced Fibrosis and Cirrhosis
por: Kilany, Shimaa, et al.
Publicado: (2021)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
por: Kamp, William M., et al.
Publicado: (2019)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients
por: El-Mahdy, Nageh Ahmed, et al.
Publicado: (2023)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
por: Guardigni, Viola, et al.
Publicado: (2017)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

The Role of Direct-acting Antivirals in the Treatment of Children with Chronic Hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2017)

Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
por: Zhang, Hang, et al.
Publicado: (2023)

Effect of direct-acting antivirals on corrected QT interval and cardiac functions in patients with chronic hepatitis C virus infection
por: Ibrahim, Mohamed Gamal, et al.
Publicado: (2020)

Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents
por: Ali, Mohamed E., et al.
Publicado: (2021)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
por: Yoo, Eric R., et al.
Publicado: (2016)

Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection
por: Salama, Iman Ibrahim, et al.
Publicado: (2022)

Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
por: El-Marakby, Mai G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h79rocsb7p09tl2rgia4n1llvk